RECURRENT DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1

Clinical trials for RECURRENT DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 explained in plain language.

Never miss a new study

Get alerted when new RECURRENT DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 trials appear

Sign up with your email to follow new studies for RECURRENT DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New drug trial aims to halt rare Cancer's spread

Disease control Ongoing

This study is testing whether a drug called pazopanib can slow or stop the growth of carcinoid tumors that are getting worse. It compares pazopanib against a placebo (inactive pill) in 171 patients whose tumors have progressed. The main goal is to see if the drug helps patients l…

Matched conditions: RECURRENT DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1

Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 17, 2026 13:08 UTC

RECURRENT DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1

Get alerted when new RECURRENT DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 trials appear

New drug trial aims to halt rare Cancer's spread